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A B S T R A C T
Background
Epileptic seizures occur in only a minority of patients with multiple sclerosis (MS), but can have serious consequences. The available
literature suggests an association of seizures in MS with cortical and subcortical demyelinating lesions, which suggest that seizures in
MS are probably most often symptomatic rather that idiopathic. It is currently unknown whether patients with MS should be treated
differently from other patients with epileptic seizures.
Objectives
To evaluate the efficacy and safety of antiepileptic treatments in patients with MS.
Search methods
We searched for double-blind, single-blind or unblinded randomised controlled trials on antiepileptic treatment in patients with MS
through electronic searches of The Cochrane Multiple Sclerosis Group’s and Cochrane Epilepsy Group’s Trials Registers, Cochrane
Central Register of Controlled Trials (The Cochrane Library 2008, Issue 1), MEDLINE (From 1966 - Jan 2008) and EMBASE (From
1974 - Jan 2008).
Selection criteria
Double-blind, single-blind or unblinded randomised controlled trials on antiepileptic treatment in patients with MS.
Data collection and analysis
Searches yielded a total of 379 citations (CENTRAL: 20, MEDLINE: 264, EMBASE: 95). We perused titles and abstracts for relevance
and independently excluded all 379 citations as clearly not meeting the inclusion criteria.
Main results
We found no studies meeting our inclusion criteria.
Authors’ conclusions
Well-designed randomised controlled trials are needed to guide clinical practice. Such trials should preferably contain a head-to-head
comparison of antiepileptic drugs in patients with MS.
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P L A I N L A N G U A G E S U M M A R Y
Treatment of seizures for patients with multiple sclerosis
Epileptic seizures occur in a relatively small number of patients with multiple sclerosis, but can have serious consequences. Because the
cause of epileptic seizures in patients in MS may be different from that in other forms of epilepsy, it is uncertain whether patients with
MS should be treated differently. We searched for studies on the treatment of epileptic seizures in patients with MS, but found none.
Well designed studies that address this issue are needed.
B A C K G R O U N D
The prevalence of epileptic seizures in patients with MS is about
3% (Poser 2003; Koch 2008) which is considerably higher than
in the general population, in which it varies between 0.5 and 1%
(Sander 2003; Forsgren 2005). Seizures are no common complaint
in MS, but can have serious consequences. The available literature
on seizures in MS suggests an association of cortical or subcortical
demyelinating lesions with the occurrence of epileptic seizures (
Koch2008), whichwouldmake seizures inMS a formof secondary
epilepsy comparable to seizures occurring in the context of stroke
or traumatic brain injury.
In view of this probable pathophysiological difference between
seizures that occur in patients with MS and those in patients with
the idiopathic epilepsy, it is uncertain whether patients with MS
should be treated differently from other patients with idiopathic
epilepsy. A systematic review of randomised controlled trials of
antiepileptic treatment in patients with MS is the best way to
resolve this uncertainty.
O B J E C T I V E S
To evaluate the efficacy and safety of antiepileptic treatment in
patients with multiple sclerosis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials on antiepileptic treatment in pa-
tients with MS. Double-blind, single-blind or unblinded trials are
included. Adequately randomised and quasi randomised trials are
included, non-randomised trials are excluded. Individual patient
data are included if available.
Types of participants
Children and adults with a diagnosis of definite MS according to
the Poser (Poser 1983) orMcDonald (McDonald 2001) diagnostic
criteria, who suffer from any form of recurrent epileptic seizure
including status epilepticus.
Types of interventions
Experimental intervention: pharmacologic and non-pharmaco-
logic interventions for the treatment of epileptic seizures without
restrictions regarding type of intervention, dose,manner of admin-
istration, frequency, or duration. Control intervention: placebo
treatment or no treatment.
Types of outcome measures
Primary outcomes
• Time from randomisation to withdrawal of allocated
treatment due to poor seizure control or side effects (retention
time). This is a combined outcome measure which encompasses
efficacy as well as tolerability (ILAE 1998).
Secondary outcomes
• Time to 12-month remission from seizures
• Time to first seizure post-randomisation
• Reduction in number of seizures until the end of follow-up
• Adverse effect rate: any adverse effect attributed to the
treatment in question
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Search methods for identification of studies
A systematic search without language restrictions was conducted
to identify all relevant published and unpublished randomised
controlled trials.
Electronic searches
(a) The Cochrane Multiple Sclerosis Group’s and Cochrane
Epilepsy Group’s Trials Registers
(b) Cochrane Central Register of Controlled Trials (CENTRAL)
“The Cochrane Library” 2008 Issue 1“ (Appendix 1)
(c) MEDLINE (From 1966 - Jan 2008) (Appendix 2)
(d) EMBASE (From 1974 - Jan 2008) (Appendix 3)
Searching other resources
(1) Checking reference tables of identified studies.
(2) Handsearching of published abstracts of conference proceed-
ings.
(3) Personal communication with authors of identified studies and
other researchers in the field.
Strategy (3) will be used to identify unpublished or ongoing stud-
ies.
Data collection and analysis
As no studies met inclusion criteria, all methods planned in the
protocol and archived for future updates canbe found in additional
Table 1.
Table 1. Table of methods archived for use in future updates
Issue Method
Selection of studies The titles and abstracts of publications identified by the above search strategy are assessed
independently for inclusion by two teams (MK/JDK and SP/MU), the full text is selected
for further assessment if the abstract suggests relevance. Papers that do not meet the
inclusion criteria are listed with the reason for omission. Disagreements are solved by
discussion
Data extraction and management Information about study population, type of intervention, outcome measures, and study
design are extracted independently from the selected studies by two teams (MK/SPMU/
JDK) on a data extraction form. Results are extracted as raw numbers. If additional
outcome data are needed, the investigators of the studies are contacted. Disagreements
are discussed, and solved by consensus
Assessment of risk of bias in included studies The methodological quality of the studies are evaluated independently by two teams of
reviewers (MK/JDK and SP/MU) according to the guidelines described in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2006). The criteria used in
the assessment of methodological quality are (1) allocation concealment, (2) method of
randomisation, (3) blinding, (4) information on loss to follow-up, and (5) blinding of
outcome assessment. Studies with a high risk of bias are included and discussed in the
text of the review, but they will be excluded from all meta-analyses. Disagreements on
the methodological quality of the identified studies among the teams of reviewers are
discussed, and solved by consensus
Measures of treatment effect For time-to-event data, treatment effects are expressed as the hazard ratio. For continuous
outcomemeasures, treatment effects are either expressed as the weightedmean difference,
or the outcome measures are dichotomised, depending on the outcome measure used
(in the event of dichotomisation, treatment effects are expressed as odds ratios)
Assessment of heterogeneity Statistical heterogeneity among the identified studies is tested for with the chi-squared
test. Significant heterogeneity among the studies is addressed by either refraining from
performing a meta-analysis altogether (in the case of serious heterogeneity), or by ex-
cluding one or a small minority of heterogenous studies. Heterogeneity is explored by
investigating the influence of subgroups (men vs. women, adults vs. children, progressive
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(Continued)
vs. non-progressive MS, blinded vs. unblinded trials, and by type of seizure)
Data synthesis The studies are summarised by meta-analysis using a fixed-effect model. Studies with
time-to-event outcomes are summarised using a modified Peto fixed-effect model, and
the hazard ratio is used as summary statistic. Studies with continuous outcomes are
summarised with the inverse variance method and the weighted mean difference is given
as summary statistic. If dichotomised outcomes are used, the studies are summarised
with the Mantel-Haenszel fixed-effect model and the odds ratio is given as summary
statistic
Publication bias is assessed with Funnel plots as outlined in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2006)
R E S U L T S
Description of studies
Results of the search
The search strategy yielded a total of 379 citations (CENTRAL:
20, MEDLINE: 264, EMBASE: 95). Two teams of reviewers
(MK/JDK and SP/MU) perused titles and abstracts for relevance
and independently excluded all 379 citations as clearly not meet-
ing the inclusion criteria. There were no disagreements regarding
study inclusion or exclusion between the two teams or between
individual team members.
Included studies
There were no included studies.
Risk of bias in included studies
No randomised controlled trials were found that fulfilled the in-
clusion criteria.
Effects of interventions
No randomised controlled trials were found that fulfilled the in-
clusion criteria.
D I S C U S S I O N
Although seizures in patients with MS occur in only a relatively
small number of patients, they can have serious consequences.
There is currently no evidence from clinical trials to guide the
clinical management of patients with seizures. The association of
seizures in MS with cortical and subcortical lesions suggests that
they are a form of secondary epilepsy and it is uncertain whether
patients should be treated according to guidelines designed for
patients with idiopathic epilepsies. Furthermore, it is uncertain
whether the tolerability of commonly used antiepileptic drugs
is the same for patients with MS and patients with idiopathic
epilepsy.
Well-designed randomised controlled trials are needed to guide
clinical practice. Such trials should preferably contain a head-to-
head comparison of antiepileptic drugs in patients with MS.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is currently no evidence to guide the treatment of epileptic
seizures in MS
Implications for research
Well-designed randomised controlled trials are needed to evaluate
efficacy and tolerability of antiepileptic treatments in patients with
MS.
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. CENTRAL (2008, Issue 1)
#1 ”multiple sclerosis“
#2 MeSH descriptor Multiple Sclerosis explode all trees
#3 ”Demyelinating disease*“
#4 MeSH descriptor Demyelinating Diseases, this term only
#5 ”transverse myelitis“
#6 MeSH descriptor Myelitis, Transverse, this term only
#7 ”neuromyelitis optica“
#8 ”optic neuritis“
#9 MeSH descriptor Optic Neuritis explode all trees
#10 MeSH descriptor Encephalomyelitis, Acute Disseminated, this term only
#11 ”encephalomyelitis acute disseminated“
#12 ”devic“
#12 MeSH descriptor Epilepsy explode all trees




#17 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12)
#18 (#12 OR #13 OR #14 OR #15 OR #16)
#20 (#17 AND #18)
Appendix 2. MEDLINE (PubMed) (1966 - Jan 2008)
((((”Multiple Sclerosis“[mh]) OR (”Myelitis, Transverse“[mh:noexp]) OR (”Demyelinating Diseases“[mh:noexp]) OR (”En-
cephalomyelitis, Acute Disseminated“[mh:noexp]) OR (”Optic Neuritis“[mh])) OR (((”multiple sclerosis“) OR (”neuromyelitis op-
tica“) OR (”transverse myelitis“) OR (encephalomyelitis) OR (devic) OR (”optic neuritis“)) OR (”demyelinating disease*“) OR (”acute
disseminated encephalomyelitis“))) AND (((randomized controlled trial[pt]) OR (controlled clinical trial[pt]) OR (randomized[tiab])
OR (placebo[tiab]) OR (drug therapy[sh]) OR (randomly[tiab]) OR (trial[tiab]) OR (groups[tiab])) NOT ((animals[mh]) NOT ((an-
imals[mh]) AND (human[mh]))))) AND ((”Epilepsy“[Mesh]) OR (”Seizures“[Mesh]) OR (epilep*) OR (seizure*) OR (convulsion*))
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Appendix 3. EMBASE (1974 - Jan 2008)
(((’encephalomyelitis’/exp)OR (’demyelinating disease’/exp)OR (’multiple sclerosis’/exp)OR (’myelooptic neuropathy’/exp)OR (’mul-
tiple sclerosis’:ti,ab) OR (’neuromyelitis optica’:ab,ti) OR (encephalomyelitis:ab,ti) OR (devic:ti,ab)) AND ((’crossover procedure’/
exp) OR (’double blind procedure’/exp) OR (’single blind procedure’/exp) OR (’randomized controlled trial’/exp) OR (random*:ab,ti)
OR (factorial*:ab,ti) OR (crossover:ab,ti) OR (cross:ab,ti AND over:ab,ti) OR (placebo:ab,ti) OR (’double blind’:ab,ti) OR (’single
blind’:ab,ti) OR (assign*:ab,ti) OR (allocat*:ab,ti) OR (volunteer*:ab,ti))) AND (((’epilepsy’/exp OR ’epilepsy’)) OR ((’seizure’/exp
OR ’seizure’)) OR (epilep*) OR (seizure*) OR (convulsion*)) AND [humans]/lim AND [embase]/lim
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Multiple Sclerosis [∗complications]; Seizures [etiology; ∗therapy]
MeSH check words
Humans
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